Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease

Rheumatology International

Volumn 33, Issue 5, 2013, Pages 1351-1353

  Mounach, Aziza ^a   Rezqi, Asmae ^a   Nouijai, Abderrazak ^a   Ghozlani, Imad ^a   Achemlal, Lahsen ^a   Maghraoui, Abdellah El ^a   Bezza, Ahmed ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Adalimumab; Rheumatoid arthritis; Severe skin reactions; Stevens Johnson syndrome

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; HEMOGLOBIN; HYDROCORTISONE; INFLIXIMAB; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; DESQUAMATION; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; REMISSION; RHEUMATOID ARTHRITIS; STEVENS JOHNSON SYNDROME; THROMBOCYTE;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; FEMALE; HUMANS; HYDROCORTISONE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 84878016732     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2212-4     Document Type: Article

References (24)

1. Feldman M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
2. Brennan FM, Maini RN, Feldman M (1998) Role of proinflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 20:133-147
3. Neidel J, Schulze M, Lindschau J (1995) Association between degree of bone erosion and synovial fluid levels of tumor necrosis factor α in the knee joints of patients with rheumatoid arthritis. Inflamm Res 44:217-221
4. Lan JL, Chou SJ, Chen DY et al (2004) A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 5-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 103:618-623
5. Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400-1411
6. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35-45
7. Braun J, Bollow M, Neure L et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499-505
8. Saxne T, Palladino MA Jr et al (1988) Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31:1041-1045
9. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132
10. Asadullah K, Docke WD, Volk HD, Sterry W (1999) The pathophysiological role of cytokines in psoriasis. Drugs Today 35:913-924
11. Delle Sedie A, Bazzichi L, Bombardieri S, Riente L (2007) Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab. Scand J Rheumatol 36:403-404
12. Esmailzadeh A et al (2009) Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 219:163-167
13. Asarch A et al (2009) Lichen-planus-like eruptions: an emerging side effect of tumor necrosis factor alpha antagonists. J Am Acad Dermatol 61:104-111
14. Wollina U et al (2008) Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 9:1-14
15. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 48:35-45
16. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdock RJ, Weinberg MA (2005) Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279-3289
17. Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-Jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J (2009) Efficacy and complications of adalimumab treatment for medically refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment Pharmacol Ther 29:527-534
18. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129:92-96
19. Roujeau JC (2006) Immune mechanisms in drug allergy. Allergol Int 55:27-33
20. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ (2007) Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 12:125-131
21. Yamamura M (2007) Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis - efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 65:1269-1275
22. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B (2007) Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8:761-773
23. Ranganathan P (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6:481-490
24. Chung CH, Mirakhur B, Chan E et al (2008) Cetuximab-induced anaphylaxis and IgE specific for galactosealpha-1,3-galactose. N Engl J Med 358:1109-1117